Firefly Neuroscience (NASDAQ:AIFF) versus Certara (NASDAQ:CERT) Critical Survey

Certara (NASDAQ:CERT) and Firefly Neuroscience (NASDAQ:AIFF) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and target prices for Certara and Firefly Neuroscience, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Certara	1	6	4	1	2.42
Firefly Neuroscience	1	0	0	0	1.00

Certara presently has a consensus target price of $8.28, indicating a potential upside of 1.54%. Given Certara’s stronger consensus rating and higher probable upside, research analysts clearly believe Certara is more favorable than Firefly Neuroscience.

Profitability

This table compares Certara and Firefly Neuroscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Certara	-16.75%	3.86%	2.65%
Firefly Neuroscience	-565.40%	-94.68%	-73.51%

Insider and Institutional Ownership

74.0% of Certara shares are held by institutional investors. Comparatively, 5.0% of Firefly Neuroscience shares are held by institutional investors. 1.1% of Certara shares are held by company insiders. Comparatively, 6.9% of Firefly Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Certara and Firefly Neuroscience”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Certara	$418.84 million	2.97	-$1.60 million	($0.45)	-18.12
Firefly Neuroscience	$1.14 million	15.82	-$19.88 million	($0.63)	-1.83

Certara has higher revenue and earnings than Firefly Neuroscience. Certara is trading at a lower price-to-earnings ratio than Firefly Neuroscience, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Certara has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Firefly Neuroscience has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.

Summary

Certara beats Firefly Neuroscience on 12 of the 15 factors compared between the two stocks.

About Certara

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

About Firefly Neuroscience

Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.